ISSN: 1746-630X

Journal Home

Journal Guideline

Current Opinion in HIV and AIDS Q1 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Opinion in HIV and AIDS is a journal indexed in SJR in Infectious Diseases and Immunology with an H index of 78. It has an SJR impact factor of 1,504 and it has a best quartile of Q1. It has an SJR impact factor of 1,504.

Current Opinion in HIV and AIDS focuses its scope in these topics and keywords: advances, hiv, usa, issues, existing, subsaharan, drugstissue, preexposure, prophylaxis, malignancies, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Hematology (Q1) Immunology (Q1) Infectious Diseases (Q1) Oncology (Q1) Oncology (nursing) (Q1) Oncology (nursing) (Q1) Virology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,504

SJR Impact factor

78

H Index

54

Total Docs (Last Year)

152

Total Docs (3 years)

3140

Total Refs

597

Total Cites (3 years)

136

Citable Docs (3 years)

3.96

Cites/Doc (2 years)

58.15

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Microbiology Q1
Clinical Microbiology Reviews Q1
The Lancet Infectious Diseases Q1
Cellular and Molecular Immunology Q1
Drug Resistance Updates Q1

Compare this journals

Aims and Scope

Best articles by citations

Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage

Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women

Interaction between HIV and Mycobacterium tuberculosis

Uptake of biomedical interventions for prevention of sexually transmitted HIV

Implementation challenges for long-acting antivirals as treatment

HIV and aging

Antibody engineering for increased potency, breadth and half-life

Epidemiology of HIV in Latin America and the Caribbean

Epidemiology of HIV-associated tuberculosis

Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)

Natural history of liver disease and effect of hepatitis C virus on HIV disease progression

Beyond cure

SHOW MORE ARTICLES

The fusion inhibitor enfuvirtide in recent antiretroviral strategies

A cure for HIV

Implementing early diagnosis and treatment

Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves

Emerging role for complement in HIV infection

The promise and pitfalls of long-acting injectable agents for HIV prevention

Financial incentives to improve progression through the HIV treatment cascade

Genomics of HIV infection

Interaction of mathematical modeling and social and behavioral HIV/AIDS research

Combined approaches for HIV cure

HIV co-receptor tropism

Current World Literature